Assembly Biosciences (NASDAQ:ASMB) Cut to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

Several other research firms have also recently issued reports on ASMB. William Blair reiterated a buy rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. BidaskClub upgraded shares of Assembly Biosciences from a strong sell rating to a sell rating in a research note on Tuesday, August 6th. Chardan Capital reiterated a hold rating and issued a $30.00 target price on shares of Assembly Biosciences in a research note on Wednesday, August 7th. Finally, ValuEngine upgraded shares of Assembly Biosciences from a hold rating to a buy rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $33.25.

NASDAQ:ASMB opened at $12.28 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.20 and a quick ratio of 9.20. Assembly Biosciences has a twelve month low of $11.49 and a twelve month high of $41.00. The company’s 50 day moving average is $13.28 and its two-hundred day moving average is $16.76.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.41. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million. As a group, research analysts forecast that Assembly Biosciences will post -3.79 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of ASMB. Nuveen Asset Management LLC acquired a new position in shares of Assembly Biosciences in the 2nd quarter valued at $3,681,000. FMR LLC lifted its stake in shares of Assembly Biosciences by 136.0% in the 4th quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock valued at $10,021,000 after purchasing an additional 255,336 shares during the period. Citadel Advisors LLC lifted its stake in shares of Assembly Biosciences by 90.0% in the 2nd quarter. Citadel Advisors LLC now owns 450,315 shares of the biopharmaceutical company’s stock valued at $6,075,000 after purchasing an additional 213,363 shares during the period. Vanguard Group Inc. lifted its stake in shares of Assembly Biosciences by 13.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock valued at $16,552,000 after purchasing an additional 146,452 shares during the period. Finally, Rock Springs Capital Management LP increased its holdings in Assembly Biosciences by 24.4% in the 2nd quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock worth $7,554,000 after acquiring an additional 110,000 shares in the last quarter. Hedge funds and other institutional investors own 85.82% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: What are convertible shares? 

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Advanced Micro Devices, Inc.  CAO Sells $281,249.64 in Stock
Insider Selling: Advanced Micro Devices, Inc. CAO Sells $281,249.64 in Stock
Jack in the Box Inc.  CEO Sells $267,000.00 in Stock
Jack in the Box Inc. CEO Sells $267,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock   Insider Buys C$270,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock Insider Buys C$270,000.00 in Stock
Blucora  Downgraded to “Sell” at Zacks Investment Research
Blucora Downgraded to “Sell” at Zacks Investment Research
Assembly Biosciences  Cut to Hold at Zacks Investment Research
Assembly Biosciences Cut to Hold at Zacks Investment Research
Aptose Biosciences  Lowered to Hold at Zacks Investment Research
Aptose Biosciences Lowered to Hold at Zacks Investment Research


© 2006-2019 Ticker Report